| Product | Statute |
|---|---|
| Aspartame (food additive) | 95 Stat. 2049, 2065 (January 4, 1982) |
| Forane (new drug) | 97 Stat. 831, 832 (October 13, 1983) |
| Impro (new animal drug) | 98 Stat. 3430 (October 19, 1984) |
| Glyburide (new drug) | 98 Stat. 3434 (October 19, 1984) |
| Lopid (new drug) | 102 Stat. 1107, 1569 (August 23, 1988) |
| Olestra (food additive) | 107 Stat. 2040 (December 3, 1993) |
| Daypro (new drug) | 110 Stat. 1321, 1321-320 (April 26, 1996) |
| Company | Net income as a percent of sales | R&D as a percent of sales | Ratio of net income to R&D |
|---|---|---|---|
| Bristol-Myers Squibb | 17.2% | 8.5% | 2.0 |
| Abbott | 18.7% | 9.8% | 1.9 |
| Merck | 19.5% | 10.6% | 1.8 |
| g744Schering-Plough | g74421.7% | ||
| Am. Home Products | 18.4% | 12.2% | 1.5 |
| Pfizer | 26.4% | 18.0% | 1.5 |
| Warner-Lambert | 12.3% | 8.6% | 1.4 |
| Johnson & Johnson | 13.0% | 10.3% | 1.3 |
| Amgen | 31.8% | 24.4% | 1.3 |
| Eli Lilly | 22.7% | 18.8% | 1.2 |
(g744Fortune Magazine's top ten pharmaceutical companies ranked by sales, in this chart in declining order by ratio of net income to R&D. Company figures from 1998 annual reports.)